Larimar exchanges 2.5M common shares for 250K convertible preferred with Blue Owl

Larimar Therapeutics, Inc.

Blue Owl Healthcare exchanged 2,500,000 common shares for 250,000 Series A convertible preferred shares.
Each preferred share converts into 10 common shares (2.5M total); conversion blocker set at 9.99%.
Preferred stock has no voting rights except on amendments; ranks pari passu with common on liquidation.
Exchange executed under Section 3(a)(9) exemption; no commissions paid.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Larimar Therapeutics, Inc. issued 250,000 shares of newly designated Series A convertible preferred stock of preferred stock to Blue Owl Healthcare Opportunities IV Public Investments LP.

Security: preferred stock
Shares: 250,000 shares of newly designated Series A convertible preferred stock
Purchaser: Blue Owl Healthcare Opportunities IV Public Investments LP

Exact text from the filing

On December 16, 2025, Larimar Therapeutics, Inc. (the “Company”) entered into an exchange agreement (the “Exchange Agreement”) with Blue Owl Healthcare Opportunities IV Public Investments LP (the “Stockholder”), pursuant to which the Stockholder exchanged 2,500,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for 250,000 shares of newly designated Series A convertible preferred stock, a “toothless” preferred stock, par value $0.001 per share (the “Preferred Stock”) (the “Exchange”).

View on SEC.gov

Browse all equity issuances →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-321738

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.